These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31706118)

  • 21. Vasopressin in septic shock.
    Dünser MW; Hasibeder WR; Wenzel V
    N Engl J Med; 2008 Jun; 358(25):2736; author reply 2737-8. PubMed ID: 18572442
    [No Abstract]   [Full Text] [Related]  

  • 22. Does body weight impact the efficacy of vasopressin therapy in the management of septic shock?
    Miller JT; Welage LS; Kraft MD; Alaniz C
    J Crit Care; 2012 Jun; 27(3):289-93. PubMed ID: 21855282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials.
    Oba Y; Lone NA
    J Crit Care; 2014 Oct; 29(5):706-10. PubMed ID: 24857641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Push-Dose Vasopressin for Hypotension in Septic Shock.
    Nowadly CD; Catlin JR; Fontenette RW
    J Emerg Med; 2020 Feb; 58(2):313-316. PubMed ID: 32173168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience.
    Russell JA; Lee T; Singer J; Boyd JH; Walley KR;
    Crit Care Med; 2017 Jun; 45(6):940-948. PubMed ID: 28333757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Septic shock--vasopressin, norepinephrine, and urgency.
    Parrillo JE
    N Engl J Med; 2008 Feb; 358(9):954-6. PubMed ID: 18305271
    [No Abstract]   [Full Text] [Related]  

  • 27. Vasopressor Therapy in the Intensive Care Unit.
    Russell JA; Gordon AC; Williams MD; Boyd JH; Walley KR; Kissoon N
    Semin Respir Crit Care Med; 2021 Feb; 42(1):59-77. PubMed ID: 32820475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock.
    Sacha GL; Lam SW; Duggal A; Torbic H; Reddy AJ; Bauer SR
    Pharmacotherapy; 2018 Mar; 38(3):319-326. PubMed ID: 29328496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasopressors to treat refractory septic shock.
    Meresse Z; Medam S; Mathieu C; Duclos G; Vincent JL; Leone M
    Minerva Anestesiol; 2020 May; 86(5):537-545. PubMed ID: 31994366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations.
    Sacha GL; Bauer SR; Lat I
    Pharmacotherapy; 2019 Mar; 39(3):369-381. PubMed ID: 30644586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Body Weight on Hemodynamic Response in Patients Receiving Fixed-Dose Vasopressin for Septic Shock.
    Hodge EK; Hughes DW; Attridge RL
    Ann Pharmacother; 2016 Oct; 50(10):816-23. PubMed ID: 27340145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of short-term vasopressin infusion during severe septic shock.
    Patel BM; Chittock DR; Russell JA; Walley KR
    Anesthesiology; 2002 Mar; 96(3):576-82. PubMed ID: 11873030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal norepinephrine-equivalent dose to initiate epinephrine in patients with septic shock.
    Ammar MA; Limberg EC; Lam SW; Ammar AA; Sacha GL; Reddy AJ; Bauer SR
    J Crit Care; 2019 Oct; 53():69-74. PubMed ID: 31202160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock.
    Hall LG; Oyen LJ; Taner CB; Cullinane DC; Baird TK; Cha SS; Sawyer MD
    Pharmacotherapy; 2004 Aug; 24(8):1002-12. PubMed ID: 15338849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
    Avni T; Lador A; Lev S; Leibovici L; Paul M; Grossman A
    PLoS One; 2015; 10(8):e0129305. PubMed ID: 26237037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Norepinephrine and Vasopressin Discontinuation Order in the Recovery Phase of Septic Shock: A Systematic Review and Individual Patient Data Meta-Analysis.
    Hammond DA; Sacha GL; Bissell BD; Musallam N; Altshuler D; Flannery AH; Lam SW; Bauer SR
    Pharmacotherapy; 2019 May; 39(5):544-552. PubMed ID: 30893494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis.
    Wu Z; Zhang S; Xu J; Xie J; Huang L; Huang Y; Yang Y; Qiu H
    Shock; 2020 Jan; 53(1):50-57. PubMed ID: 31008869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.
    Erwin BL; Denaburg MA; Barker AB; McArdle PJ; Windham ST; Morgan CJ
    Crit Care Med; 2017 Dec; 45(12):e1226-e1232. PubMed ID: 28991825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.